Gooch & Housego (GHH) H2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2025 earnings summary
11 Mar, 2026Executive summary
Revenue increased by 10.7% to £150.5 million, driven by strong Aerospace & Defence (A&D) growth and strategic acquisitions.
Adjusted profit before tax rose 46.8% to £11.9 million, with sustainable margin improvement and gross margin up to 31.0%.
Record order book at £142.3 million, up 36.2%, with continued growth post year-end and significant A&D pipeline.
Successfully integrated Phoenix Optical Technologies and Global Photonics, enhancing US defense and Germanium capabilities.
Maintained operational resilience despite macroeconomic and supply chain challenges.
Financial highlights
Adjusted operating profit increased 37.3% to £14.4 million; margin up 186bps to 9.6%.
Adjusted profit before tax rose 46.8% to £11.9 million from £8.1 million year-over-year.
Net bank debt at £29.9 million after £10.1 million in acquisitions and £7.5 million in strategic inventory investments.
Final dividend declared at 8.3p, total dividend 13.2p.
Adjusted basic EPS up 38.8% to 35.4p; reported profit before tax £5.3 million (up 26.6%).
Outlook and guidance
Board expectations for FY2026 remain unchanged, with confidence in continued profitable growth.
Order intake of £178.6 million in FY2025, book-to-bill above 1.2; order book covers 80% of FY2026 revenue.
Strong A&D growth expected to continue; semiconductor market recovery subdued.
Germanium supply remains variable and H2 weighted.
Positive medium-term outlook for all segments, especially aerospace and defense.
Latest events from Gooch & Housego
- Revenue up, profit down; strong order book and A&D/Life Sciences offset industrial weakness.GHH
H2 202411 Mar 2026 - Revenue and profit fell, but improved margins and a strong order book support a positive outlook.GHH
H1 202411 Mar 2026 - Acquisition creates a U.S. optical systems hub, boosting defense capabilities and growth potential.GHH
M&A announcement11 Mar 2026 - Revenue and profit surged, led by A&D and Life Sciences, with strong order cover for FY2025.GHH
H1 202511 Mar 2026 - Solid FY2024 results and acquisitions set the stage for growth in Life Sciences and Defence.GHH
Investor presentation11 Mar 2026 - Order book grew to £126.4M, driven by innovation, acquisitions, and operational improvements.GHH
AGM 2025 presentation11 Mar 2026 - Double-digit revenue growth and record order intake driven by A&D and new technology focus.GHH
AGM 2026 presentation11 Mar 2026 - Revenue delays impact FY2024, but strategic progress and FY2025 outlook remain strong.GHH
Trading update11 Mar 2026 - Strong second half trading and robust cash generation position the group for next year's recovery.GHH
Trading update11 Mar 2026